Table 1.
Characteristics of the studied population divided based on disease activity.
| Low (DAPSA ≤ 14) (N = 18) |
Moderate and high (DAPSA > 14) (N = 37) |
P | |||
|---|---|---|---|---|---|
| Age (years), median (IQR) | 50.5 | 47.0–63.0 | 54.0 | 46.0–59.0 | 0.699 |
| Female sex N (%) | 12 | 66.7 | 21 | 56.8 | 0.565 |
| Body mass index (BMI), median (IQR) | 23.4 | 22.1–24.3 | 25.7 | 23.9–27.7 | 0.007* |
| Systolic BP (mmHg), median (IQR) | 130 | 110–135 | 130 | 120–140 | 0.265 |
| Diastolic BP (mmHg), median (IQR) | 70 | 70–80 | 70 | 70–80 | 0.957 |
| Duration of PsA (years), median (IQR) | 3.5 | 2.3–7.0 | 7.0 | 5.0–13.0 | 0.013* |
| Duration of psoriasis (years), median (IQR) | 4.5 | 3.0–18.5 | 12.0 | 6.0–20.5 | 0.106 |
| PsA onset in relation to psoriasis diagnosis | 0.237 | ||||
| Prior N (%) | 5 | 27.8 | 6 | 16.2 | |
| During N (%) | 5 | 27.8 | 8 | 21.6 | |
| After N (%) | 6 | 33.3 | 23 | 62.2 | |
| Dactylitis present N (%) | 1 | 5.5 | 18 | 48.6 | 0.004* |
| Sacroiliitis present N (%) | 4 | 22.2 | 14 | 37.9 | 0.529 |
| Systemic glucocorticoids N (%) | 2 | 11.1 | 7 | 18.9 | 0.702 |
| Disease Modifying Anti-Rheumatic Drugs (DMARD) | 0.425 | ||||
| None N (%) | 3 | 16.7 | 2 | 5.4 | |
| Leflunomid N (%) | 2 | 11.1 | 8 | 21.7 | |
| Methotrexate N (%) | 6 | 33.3 | 15 | 40.5 | |
| Salazopyrin N (%) | 3 | 16.7 | 4 | 10.9 | |
| Methotrexate + leflunomide N (%) | 0 | 0.0 | 2 | 5.4 | |
| Salazopyrin + leflunomid N (%) | 0 | 0.0 | 2 | 5.4 | |
| Biologic therapy N (%) | 6 | 33.3 | 17 | 45.9 | 1.000 |
| Duration of biologic therapy (years), median (IQR) | 3.0 | 1.0–6.0 | 3.0 | 2.0–7.5 | 0.755 |
| Type of biologic therapy | 0.216 | ||||
| Certolizumab N (%) | 0 | 0.0 | 2 | 5.4 | |
| Sekukinumab N (%) | 1 | 5.5 | 4 | 10.8 | |
| Etanercept N (%) | 1 | 5.5 | 1 | 2.7 | |
| Adalimumab N (%) | 0 | 0.0 | 7 | 18.9 | |
| Infliksimab N (%) | 2 | 11.1 | 1 | 2.7 | |
| Golimumab N (%) | 2 | 11.1 | 1 | 2.7 | |
| Routine laboratory evaluation | |||||
| Erythrocyte sedimentation rate, median (IQR) | 9.5 | 5.0–13.9 | 11.0 | 4.0–22.0 | 0.382 |
| Thrombocytes (×109/L), median (IQR) | 232.0 | 213–283 | 243.0 | 210–270 | 0.920 |
| Fasting glucose (mmol/L), | 5.1 | 4.6–5.5 | 5.3 | 4.7–5.9 | 0.579 |
| Uric acid (µmol/l), | 239.0 | 220–320 | 289.5 | 251–366 | 0.058 |
| C-reactive protein (CRP) (mg/L), median (IQR) | 1.4 | 0.7–2.5 | 4.5 | 2.5–10.8 | < 0.001* |
| Total cholesterol (mmol/L), median (IQR) | 6.0 | 4.9–6.2 | 5.6 | 4.7–6.6 | 0.794 |
| Triglycerides (mmol/L), median (IQR) | 1.0 | 0.8–1.3 | 1.3 | 0.9–2.3 | 0.056 |
| High-density lipoprotein (HDL) (mmol/L), median (IQR) | 1.5 | 1.2–1.7 | 1.3 | 1.1–1.7 | 0.241 |
| Psoriasis area and severity index (PASI score), median (IQR) | 0.3 | 00–1.25 | 1.3 | 0.6–4.8 | 0.009 |
* statistically significant (P < 0.05).